Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.

Saved in:
Bibliographic Details
Title: Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension.
Authors: Adeshara K; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lithovius R; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mutter S; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Harjutsalo V; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Lehto M; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Groop PH; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. per-henrik.groop@helsinki.fi.; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi., Sandholm N; Folkhälsan Research Center, Haartmaninkatu 8, FI-00290, Helsinki, Finland. niina.sandholm@helsinki.fi.; Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. niina.sandholm@helsinki.fi.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. niina.sandholm@helsinki.fi.
Corporate Authors: FinnDiane Study Group
Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2025 Dec 12; Vol. 25 (1), pp. 13. Date of Electronic Publication: 2025 Dec 12.
Publication Type: Journal Article; Observational Study
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1475-2840
DOI:10.1186/s12933-025-03017-8